These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37405390)

  • 1. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery.
    Kamath S; Stringer AM; Prestidge CA; Joyce P
    Expert Opin Drug Deliv; 2023; 20(10):1315-1331. PubMed ID: 37405390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of common pharmaceutical excipients on the gut microbiota.
    Subramaniam S; Kamath S; Ariaee A; Prestidge C; Joyce P
    Expert Opin Drug Deliv; 2023; 20(10):1297-1314. PubMed ID: 37307224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
    Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anorexia nervosa and gut microbiome: implications for weight change and novel treatments.
    Wei Y; Peng S; Lian C; Kang Q; Chen J
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):321-332. PubMed ID: 35303781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out.
    Conti G; D'Amico F; Fabbrini M; Brigidi P; Barone M; Turroni S
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Strategies to Modulate the Gut Microbiome and Immune System.
    Han K; Xu J; Xie F; Crowther J; Moon JJ
    J Immunol; 2024 Jan; 212(2):208-215. PubMed ID: 38166246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the Microbiome for Crohn's Disease Treatment.
    Gowen R; Gamal A; Di Martino L; McCormick TS; Ghannoum MA
    Gastroenterology; 2023 Apr; 164(5):828-840. PubMed ID: 36702360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
    Sharma A; Buschmann MM; Gilbert JA
    Clin Pharmacol Ther; 2019 Aug; 106(2):317-328. PubMed ID: 30937887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bringing pharmacomicrobiomics to the clinic through well-designed studies.
    Steiner HE; Patterson HK; Giles JB; Karnes JH
    Clin Transl Sci; 2022 Oct; 15(10):2303-2315. PubMed ID: 35899413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota: what is its place in pharmacology?
    Tarasiuk A; Fichna J
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):921-930. PubMed ID: 31544557
    [No Abstract]   [Full Text] [Related]  

  • 11. Interaction between drugs and the gut microbiome.
    Weersma RK; Zhernakova A; Fu J
    Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.
    Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER
    Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota medicine: towards clinical revolution.
    Gebrayel P; Nicco C; Al Khodor S; Bilinski J; Caselli E; Comelli EM; Egert M; Giaroni C; Karpinski TM; Loniewski I; Mulak A; Reygner J; Samczuk P; Serino M; Sikora M; Terranegra A; Ufnal M; Villeger R; Pichon C; Konturek P; Edeas M
    J Transl Med; 2022 Mar; 20(1):111. PubMed ID: 35255932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human gut microbiota/microbiome in health and diseases: a review.
    Gomaa EZ
    Antonie Van Leeuwenhoek; 2020 Dec; 113(12):2019-2040. PubMed ID: 33136284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbial modulation of the gut microbiome for treating autoimmune diseases.
    Balakrishnan B; Taneja V
    Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):985-996. PubMed ID: 30146910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.
    Jia L; Huang S; Sun B; Shang Y; Zhu C
    Front Endocrinol (Lausanne); 2023; 14():1149256. PubMed ID: 37033254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism.
    Dikeocha IJ; Al-Kabsi AM; Miftahussurur M; Alshawsh MA
    FASEB J; 2022 Jun; 36(6):e22350. PubMed ID: 35579628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-microbiota interactions: an emerging priority for precision medicine.
    Zhao Q; Chen Y; Huang W; Zhou H; Zhang W
    Signal Transduct Target Ther; 2023 Oct; 8(1):386. PubMed ID: 37806986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Reciprocal Link between Oral, Gut Microbiota during Periodontitis: The Potential Role of Probiotics in Reducing Dysbiosis-Induced Inflammation.
    Di Stefano M; Santonocito S; Polizzi A; Mauceri R; Troiano G; Lo Giudice A; Romano A; Mascitti M; Isola G
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting gut microbiome: A novel and potential therapy for autism.
    Yang Y; Tian J; Yang B
    Life Sci; 2018 Feb; 194():111-119. PubMed ID: 29277311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.